Close Bookmark and Share This Page

Save to Browser Favorites / Bookmarks

Ask backflip blinklist BlogBookmark Bloglines BlogMarks Blogsvine BuddyMarks BUMPzee! CiteULike Connotea del.icio.us

Digg diigo DotNetKicks DropJack dzone Facebook Fark Faves Friendsite folkd.com Furl Google

Jamespot Jeqq Kaboodle kirtsy linkaGoGo LinkedIn Ma.gnolia Mister Wong Mixx MySpace Netvouz Newsvine

oneview OnlyWire PlugIM Propeller Reddit Segnalo Shoutwire Simpy Slashdot Surphace Sphinn Spurl

Squidoo StumbleUpon Technorati ThisNext Twitter Webride Windows Live Yahoo!

Email This to a Friend

  Link HTML: 

 Permalink: 

 If you like this then please subscribe to the RSS Feed.

Powered by Bookmarkify™

More »

Swiss pharmaceutical giant Roche Holding AG’s (RHHBY.PK:News ) unit Genentech Monday stated that its investigational drug vismodegib showed positive results in a pivotal phase II study in people with basal cell carcinoma, an advanced form of skin cancer.

According to the American Cancer Society, skin cancer is the most common type of all known cancers and over 2 million skin cancers are diagnosed annually. Eighty percent of these are basal cell carcinomas or BCCs, which grow slowly from the bottom (basal), layer of the epidermis, or the outer skin layer.

Full article

Regards,

Don